The design and synthesis of a series of peptide derivatives based on a short ACE2 α-helix 1 epitope and subsequent [i - i+4] stapling of the secondary structure resulted in the identification of a 9-mer peptide capable to compete with recombinant ACE2 towards Spike RBD in the micromolar range. Specifically, SARS-CoV-2 Spike inhibitor screening based on colorimetric ELISA assay and structural studies by circular dichroism showed the ring-closing metathesis cyclization being capable to stabilize the helical structure of the 9-mer 34HEAEDLFYQ42 epitope better than the triazole stapling via click chemistry. MD simulations showed the stapled peptide being able not only to bind the Spike RBD, sterically interfering with ACE2, but also showing higher affinity to the target as compared to parent epitope.
In maximally Ca2+-activated demembranated fibres from the mammalian skeletal muscle, the depression of the force by lowering the temperature below the physiological level (~35 °C) is explained by the reduction of force in the myosin motor. Instead, cooling is reported to not affect the force per motor in Ca2+-activated cardiac trabeculae from the rat ventricle. Here, the mechanism of the cardiac performance depression by cooling is reinvestigated with fast sarcomere-level mechanics. We determine the changes in the half-sarcomere compliance of maximally Ca2+-activated demembranated rat trabeculae in the range of temperatures of 10–30 °C and analyse the data in terms of a simplified mechanical model of the half-sarcomere to extract the contribution of myofilaments and myosin motors. We find that the changes in the ensemble force are due to changes in the force per motor, while the fraction of actin-attached motors remains constant independent of temperature. The results demonstrate that in the cardiac myosin, as in the skeletal muscle myosin, the force-generating transition is endothermic. The underlying large heat absorption indicates the interaction of extended hydrophobic surfaces within the myosin motor, like those suggested by the crystallographic model of the working stroke.
Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle disorder caused by the absence of dystrophin, resulting in progressive membrane instability, impaired force transmission, and muscle degeneration. Current adeno-associated virus (AAV)-based gene replacement strategies rely on truncated dystrophin variants due to vector cargo limitations, yet the determinants of their therapeutic efficacy remain poorly understood. Here, we investigated how dystrophin domain composition influences membrane stabilization and muscle performance by comparing micro-dystrophin (µDys) with two larger Midi-dystrophin variants generated using a dual myotropic AAV trans-splicing intein-based system. Using human DMD muscle organoids and mouse models, we show that µDys provides significant histological and functional improvement but limited protection against contraction-induced mechanical stress. In contrast, larger dystrophin variants achieved superior functional rescue, with efficacy strongly dependent on domain architecture. A membrane binding-enriched Midi-dystrophin improved sarcolemmal stability, mechanical resistance, protection of fast-twitch fibres, and restoration of dystrophin-associated protein interactions. Together, these findings demonstrate that dystrophin domain composition, rather than size alone, determines therapeutic efficacy and provide a framework for domain-guided engineering of next-generation DMD gene therapies.